SEARCH

SEARCH BY CITATION

References

  • 1
    William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011; 8: 6119.
  • 2
    Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 2011; 37: 14350.
  • 3
    Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer – do we have more choice? Br J Cancer 2010; 102: 62938.
  • 4
    Bridle BW. Neuroendocrine cancer vaccines in clinical trials. Expert Rev Vaccines 2011; 10: 81123.
  • 5
    Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev Vaccines 2010; 9: 32335.
  • 6
    Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 33744.
  • 7
    Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 10019.
  • 8
    Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 184352.
  • 9
    Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795801.
  • 10
    Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 92937.
  • 11
    Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 126679.
  • 12
    Yoshida K, Noguchi M, Mine T et al. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncol Rep 2011; 25: 5762.
  • 13
    Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 9706.
  • 14
    Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64: 53545.
  • 15
    Kinoshita Y, Kuratsukuri K, Landas S et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30: 62836.
  • 16
    Quintero IB, Araujo CL, Pulkka AE et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res 2007; 67: 654954.
  • 17
    Wang Y, Harada M, Yano H et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 2005; 28: 53541.
  • 18
    Wang Y, Harada M, Yano H et al. Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients. Oncol Rep 2006; 15: 31721.
  • 19
    Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 87887.
  • 20
    Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010; 10: 98391.
  • 21
    Neninger E, Díaz RM, de la Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 14550.
  • 22
    Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23: 685464.
  • 23
    von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7: 118191.
  • 24
    Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29: 295301.